Skip to main content
Top
Published in: Breast Cancer Research 5/2014

Open Access 01-10-2014 | Research article

Leptin induces upregulation of sphingosine kinase 1 in oestrogen receptor-negative breast cancer via Src family kinase-mediated, janus kinase 2-independent pathway

Authors: Heba Alshaker, Jonathan Krell, Adam E Frampton, Jonathan Waxman, Oleg Blyuss, Alexey Zaikin, Mathias Winkler, Justin Stebbing, Ernesto Yagüe, Dmitri Pchejetski

Published in: Breast Cancer Research | Issue 5/2014

Login to get access

Abstract

Introduction

Obesity is a known risk factor for breast cancer. Sphingosine kinase 1 (SK1) is an oncogenic lipid kinase that is overexpressed in breast tumours and linked with poor prognosis, however, its role in obesity-driven breast cancer was never elucidated.

Methods

Human primary and secondary breast cancer tissues were analysed for SK1 and leptin receptor expression using quantitative real-time polymerase chain reaction (qRT-PCR) assay. Leptin-induced signalling was analysed in human oestrogen receptor (ER)-positive and negative breast cancer cells using Western blotting, qRT-PCR and radiolabelling assays.

Results

Our findings show for the first time that human primary breast tumours and associated lymph node metastases exhibit a strong correlation between SK1 and leptin receptor expression (Pearson R = 0.78 and R = 0.77, respectively, P <0.001). Both these genes are elevated in metastases of ER-negative patients and show a significant increase in patients with higher body mass index (BMI). Leptin induces SK1 expression and activation in ER-negative breast cancer cell lines MDAMB-231 and BT-549, but not in ER-positive cell lines. Pharmacological inhibition and gene knockdown showed that leptin-induced SK1 activity and expression are mediated by activation of extracellular signal-regulated kinases 1/2 (ERK1/2) and Src family kinase (SFK) pathways, but not by the major pathways downstream of leptin receptor (LEPR) - janus kinase 2 (JAK2) and signal transducer and activator of transcription 3 (STAT3). Src-homology 2 domain-containing phosphatase 2 (SHP2) appeared to be key to SK1 activation, and may function as an adaptor protein between SFKs and LEPR. Importantly, leptin-induced breast cancer cell proliferation was abrogated by SK1-specific small interfering RNA (siRNA).

Conclusions

Overall, our findings demonstrate a novel SFK/ERK1/2-mediated pathway that links leptin signalling and expression of oncogenic enzyme SK1 in breast tumours and suggest the potential significance of this pathway in ER-negative breast cancer.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kelly T, Yang W, Chen CS, Reynolds K, He J: Global burden of obesity in 2005 and projections to 2030. Int J Obes. 2008, 32: 1431-1437. 10.1038/ijo.2008.102.CrossRef Kelly T, Yang W, Chen CS, Reynolds K, He J: Global burden of obesity in 2005 and projections to 2030. Int J Obes. 2008, 32: 1431-1437. 10.1038/ijo.2008.102.CrossRef
3.
go back to reference Maccio A, Madeddu C, Gramignano G, Mulas C, Floris C, Massa D, Astara G, Chessa P, Mantovani G: Correlation of body mass index and leptin with tumor size and stage of disease in hormone-dependent postmenopausal breast cancer: preliminary results and therapeutic implications. J Mol Med (Berl). 2010, 88: 677-686. 10.1007/s00109-010-0611-8.CrossRef Maccio A, Madeddu C, Gramignano G, Mulas C, Floris C, Massa D, Astara G, Chessa P, Mantovani G: Correlation of body mass index and leptin with tumor size and stage of disease in hormone-dependent postmenopausal breast cancer: preliminary results and therapeutic implications. J Mol Med (Berl). 2010, 88: 677-686. 10.1007/s00109-010-0611-8.CrossRef
4.
go back to reference Anderson GL, Neuhouser ML: Obesity and the risk for premenopausal and postmenopausal breast cancer. Cancer Prev Res. 2012, 5: 515-521. 10.1158/1940-6207.CAPR-12-0091.CrossRef Anderson GL, Neuhouser ML: Obesity and the risk for premenopausal and postmenopausal breast cancer. Cancer Prev Res. 2012, 5: 515-521. 10.1158/1940-6207.CAPR-12-0091.CrossRef
5.
go back to reference Miyoshi Y, Funahashi T, Tanaka S, Taguchi T, Tamaki Y, Shimomura I, Noguchi S: High expression of leptin receptor mRNA in breast cancer tissue predicts poor prognosis for patients with high, but not low, serum leptin levels. Int J Cancer. 2006, 118: 1414-1419. 10.1002/ijc.21543.CrossRefPubMed Miyoshi Y, Funahashi T, Tanaka S, Taguchi T, Tamaki Y, Shimomura I, Noguchi S: High expression of leptin receptor mRNA in breast cancer tissue predicts poor prognosis for patients with high, but not low, serum leptin levels. Int J Cancer. 2006, 118: 1414-1419. 10.1002/ijc.21543.CrossRefPubMed
6.
go back to reference Ishikawa M, Kitayama J, Nagawa H: Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. Clin Cancer Res. 2004, 10: 4325-4331. 10.1158/1078-0432.CCR-03-0749.CrossRefPubMed Ishikawa M, Kitayama J, Nagawa H: Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. Clin Cancer Res. 2004, 10: 4325-4331. 10.1158/1078-0432.CCR-03-0749.CrossRefPubMed
7.
go back to reference Zheng Q, Dunlap SM, Zhu J, Downs-Kelly E, Rich JN, Hursting SD, Berger NA, Reizes O: Leptin deficiency suppresses MMTV-Wnt-1 mammary tumor growth and abrogates tumor initiating cell survival. Endocr Relat Cancer. 2011, 18: 491-503. 10.1530/ERC-11-0102.CrossRefPubMedPubMedCentral Zheng Q, Dunlap SM, Zhu J, Downs-Kelly E, Rich JN, Hursting SD, Berger NA, Reizes O: Leptin deficiency suppresses MMTV-Wnt-1 mammary tumor growth and abrogates tumor initiating cell survival. Endocr Relat Cancer. 2011, 18: 491-503. 10.1530/ERC-11-0102.CrossRefPubMedPubMedCentral
8.
go back to reference Zabeau L, Lavens D, Peelman F, Eyckerman S, Vandekerckhove J, Tavernier J: The ins and outs of leptin receptor activation. FEBS Lett. 2003, 546: 45-50. 10.1016/S0014-5793(03)00440-X.CrossRefPubMed Zabeau L, Lavens D, Peelman F, Eyckerman S, Vandekerckhove J, Tavernier J: The ins and outs of leptin receptor activation. FEBS Lett. 2003, 546: 45-50. 10.1016/S0014-5793(03)00440-X.CrossRefPubMed
9.
go back to reference Ando S, Catalano S: The multifactorial role of leptin in driving the breast cancer microenvironment. Nat Rev Endocrinol. 2011, 8: 263-275. 10.1038/nrendo.2011.184.CrossRefPubMed Ando S, Catalano S: The multifactorial role of leptin in driving the breast cancer microenvironment. Nat Rev Endocrinol. 2011, 8: 263-275. 10.1038/nrendo.2011.184.CrossRefPubMed
10.
go back to reference Jiang L, Li Z, Rui L: Leptin stimulates both JAK2-dependent and JAK2-independent signaling pathways. J Biol Chem. 2008, 283: 28066-28073. 10.1074/jbc.M805545200.CrossRefPubMedPubMedCentral Jiang L, Li Z, Rui L: Leptin stimulates both JAK2-dependent and JAK2-independent signaling pathways. J Biol Chem. 2008, 283: 28066-28073. 10.1074/jbc.M805545200.CrossRefPubMedPubMedCentral
11.
go back to reference Ray A, Nkhata KJ, Cleary MP: Effects of leptin on human breast cancer cell lines in relationship to estrogen receptor and HER2 status. Int J Oncol. 2007, 30: 1499-1509.PubMed Ray A, Nkhata KJ, Cleary MP: Effects of leptin on human breast cancer cell lines in relationship to estrogen receptor and HER2 status. Int J Oncol. 2007, 30: 1499-1509.PubMed
12.
go back to reference Gonzalez RR, Watters A, Xu YB, Singh UP, Mann DR, Rueda BR, Penichet ML: Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer. Breast Cancer Res. 2009, 11: R36-10.1186/bcr2321.CrossRef Gonzalez RR, Watters A, Xu YB, Singh UP, Mann DR, Rueda BR, Penichet ML: Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer. Breast Cancer Res. 2009, 11: R36-10.1186/bcr2321.CrossRef
13.
go back to reference Alshaker H, Sauer L, Monteil D, Ottaviani S, Srivats S, Bohler T, Pchejetski D: Therapeutic potential of targeting SK1 in human cancers. Adv Cancer Res. 2013, 117: 143-200. 10.1016/B978-0-12-394274-6.00006-6.CrossRefPubMed Alshaker H, Sauer L, Monteil D, Ottaviani S, Srivats S, Bohler T, Pchejetski D: Therapeutic potential of targeting SK1 in human cancers. Adv Cancer Res. 2013, 117: 143-200. 10.1016/B978-0-12-394274-6.00006-6.CrossRefPubMed
14.
go back to reference French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL, Yun JK, Smith CD: Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res. 2003, 63: 5962-5969.PubMed French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL, Yun JK, Smith CD: Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res. 2003, 63: 5962-5969.PubMed
15.
go back to reference Van Brocklyn JR, Jackson CA, Pearl DK, Kotur MS, Snyder PJ, Prior TW: Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines. J Neuropathol Exp Neurol. 2005, 64: 695-705. 10.1097/01.jnen.0000175329.59092.2c.CrossRefPubMed Van Brocklyn JR, Jackson CA, Pearl DK, Kotur MS, Snyder PJ, Prior TW: Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines. J Neuropathol Exp Neurol. 2005, 64: 695-705. 10.1097/01.jnen.0000175329.59092.2c.CrossRefPubMed
16.
go back to reference Ling BB, Chen LF, Alcorn J, Ma BH, Yang JA: Sphingosine-1-phosphate: a potential therapeutic agent against human breast cancer. Invest New Drugs. 2011, 29: 396-399. 10.1007/s10637-009-9375-9.CrossRefPubMed Ling BB, Chen LF, Alcorn J, Ma BH, Yang JA: Sphingosine-1-phosphate: a potential therapeutic agent against human breast cancer. Invest New Drugs. 2011, 29: 396-399. 10.1007/s10637-009-9375-9.CrossRefPubMed
17.
go back to reference Ruckhaberle E, Rody A, Engels K, Gaetje R, von Minckwitz G, Schiffmann S, Grosch S, Geisslinger G, Holtrich U, Karn T, Kaufmann M: Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat. 2008, 112: 41-52. 10.1007/s10549-007-9836-9.CrossRefPubMed Ruckhaberle E, Rody A, Engels K, Gaetje R, von Minckwitz G, Schiffmann S, Grosch S, Geisslinger G, Holtrich U, Karn T, Kaufmann M: Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat. 2008, 112: 41-52. 10.1007/s10549-007-9836-9.CrossRefPubMed
18.
go back to reference Blachnio-Zabielska AU, Pulka M, Baranowski M, Nikolajuk A, Zabielski P, Gorska M, Gorski J: Ceramide metabolism is affected by obesity and diabetes in human adipose tissue. J Cell Physiol. 2012, 227: 550-557. 10.1002/jcp.22745.CrossRefPubMed Blachnio-Zabielska AU, Pulka M, Baranowski M, Nikolajuk A, Zabielski P, Gorska M, Gorski J: Ceramide metabolism is affected by obesity and diabetes in human adipose tissue. J Cell Physiol. 2012, 227: 550-557. 10.1002/jcp.22745.CrossRefPubMed
19.
go back to reference Sauer L, Nunes J, Salunkhe V, Skalska L, Kohama T, Cuvillier O, Waxman J, Pchejetski D: Sphingosine kinase 1 inhibition sensitizes hormone-resistant prostate cancer to docetaxel. Int J Cancer. 2009, 125: 2728-2736. 10.1002/ijc.24640.CrossRefPubMed Sauer L, Nunes J, Salunkhe V, Skalska L, Kohama T, Cuvillier O, Waxman J, Pchejetski D: Sphingosine kinase 1 inhibition sensitizes hormone-resistant prostate cancer to docetaxel. Int J Cancer. 2009, 125: 2728-2736. 10.1002/ijc.24640.CrossRefPubMed
20.
go back to reference Pchejetski D, Nunes J, Coughlan K, Lall H, Pitson SM, Waxman J, Sumbayev VV: The involvement of sphingosine kinase 1 in LPS-induced Toll-like receptor 4-mediated accumulation of HIF-1alpha protein, activation of ASK1 and production of the pro-inflammatory cytokine IL-6. Immunol Cell Biol. 2011, 89: 268-274. 10.1038/icb.2010.91.CrossRefPubMed Pchejetski D, Nunes J, Coughlan K, Lall H, Pitson SM, Waxman J, Sumbayev VV: The involvement of sphingosine kinase 1 in LPS-induced Toll-like receptor 4-mediated accumulation of HIF-1alpha protein, activation of ASK1 and production of the pro-inflammatory cytokine IL-6. Immunol Cell Biol. 2011, 89: 268-274. 10.1038/icb.2010.91.CrossRefPubMed
21.
go back to reference Bonhoure E, Pchejetski D, Aouali N, Morjani H, Levade T, Kohama T, Cuvillier O: Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1. Leukemia. 2006, 20: 95-102. 10.1038/sj.leu.2404023.CrossRefPubMed Bonhoure E, Pchejetski D, Aouali N, Morjani H, Levade T, Kohama T, Cuvillier O: Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1. Leukemia. 2006, 20: 95-102. 10.1038/sj.leu.2404023.CrossRefPubMed
22.
go back to reference Gharbi SI, Zvelebil MJ, Shuttleworth SJ, Hancox T, Saghir N, Timms JF, Waterfield MD: Exploring the specificity of the PI3K family inhibitor LY294002. Biochem J. 2007, 404: 15-21. 10.1042/BJ20061489.CrossRefPubMedPubMedCentral Gharbi SI, Zvelebil MJ, Shuttleworth SJ, Hancox T, Saghir N, Timms JF, Waterfield MD: Exploring the specificity of the PI3K family inhibitor LY294002. Biochem J. 2007, 404: 15-21. 10.1042/BJ20061489.CrossRefPubMedPubMedCentral
23.
go back to reference Walter AO, Peng ZY, Cartwright CA: The Shp-2 tyrosine phosphatase activates the Src tyrosine kinase by a non-enzymatic mechanism. Oncogene. 1999, 18: 1911-1920. 10.1038/sj.onc.1202513.CrossRefPubMed Walter AO, Peng ZY, Cartwright CA: The Shp-2 tyrosine phosphatase activates the Src tyrosine kinase by a non-enzymatic mechanism. Oncogene. 1999, 18: 1911-1920. 10.1038/sj.onc.1202513.CrossRefPubMed
24.
go back to reference Goodwin PJ, Ennis M, Fantus IG, Pritchard KI, Trudeau ME, Koo J, Hood N: Is leptin a mediator of adverse prognostic effects of obesity in breast cancer?. J Clin Oncol. 2005, 23: 6037-6042. 10.1200/JCO.2005.02.048.CrossRefPubMed Goodwin PJ, Ennis M, Fantus IG, Pritchard KI, Trudeau ME, Koo J, Hood N: Is leptin a mediator of adverse prognostic effects of obesity in breast cancer?. J Clin Oncol. 2005, 23: 6037-6042. 10.1200/JCO.2005.02.048.CrossRefPubMed
25.
go back to reference Maceyka M, Alvarez SE, Milstien S, Spiegel S: Filamin A links sphingosine kinase 1 and sphingosine-1-phosphate receptor 1 at lamellipodia to orchestrate cell migration. Mol Cell Biol. 2008, 28: 5687-5697. 10.1128/MCB.00465-08.CrossRefPubMedPubMedCentral Maceyka M, Alvarez SE, Milstien S, Spiegel S: Filamin A links sphingosine kinase 1 and sphingosine-1-phosphate receptor 1 at lamellipodia to orchestrate cell migration. Mol Cell Biol. 2008, 28: 5687-5697. 10.1128/MCB.00465-08.CrossRefPubMedPubMedCentral
26.
go back to reference Bryan L, Paugh BS, Kapitonov D, Wilczynska KM, Alvarez SM, Singh SK, Milstien S, Spiegel S, Kordula T: Sphingosine-1-phosphate and interleukin-1 independently regulate plasminogen activator inhibitor-1 and urokinase-type plasminogen activator receptor expression in glioblastoma cells: implications for invasiveness. Mol Cancer Res. 2008, 6: 1469-1477. 10.1158/1541-7786.MCR-08-0082.CrossRefPubMedPubMedCentral Bryan L, Paugh BS, Kapitonov D, Wilczynska KM, Alvarez SM, Singh SK, Milstien S, Spiegel S, Kordula T: Sphingosine-1-phosphate and interleukin-1 independently regulate plasminogen activator inhibitor-1 and urokinase-type plasminogen activator receptor expression in glioblastoma cells: implications for invasiveness. Mol Cancer Res. 2008, 6: 1469-1477. 10.1158/1541-7786.MCR-08-0082.CrossRefPubMedPubMedCentral
27.
go back to reference Nagahashi M, Ramachandran S, Kim EY, Allegood JC, Rashid OM, Yamada A, Zhao R, Milstien S, Zhou H, Spiegel S, Takabe K: Sphingosine-1-phosphate produced by sphingosine kinase 1 promotes breast cancer progression by stimulating angiogenesis and lymphangiogenesis. Cancer Res. 2012, 72: 726-735. 10.1158/0008-5472.CAN-11-2167.CrossRefPubMedPubMedCentral Nagahashi M, Ramachandran S, Kim EY, Allegood JC, Rashid OM, Yamada A, Zhao R, Milstien S, Zhou H, Spiegel S, Takabe K: Sphingosine-1-phosphate produced by sphingosine kinase 1 promotes breast cancer progression by stimulating angiogenesis and lymphangiogenesis. Cancer Res. 2012, 72: 726-735. 10.1158/0008-5472.CAN-11-2167.CrossRefPubMedPubMedCentral
28.
go back to reference Liu CL, Chang YC, Cheng SP, Chern SR, Yang TL, Lee JJ, Guo IC, Chen CP: The roles of serum leptin concentration and polymorphism in leptin receptor gene at codon 109 in breast cancer. Oncology. 2007, 72: 75-81. 10.1159/000111097.CrossRefPubMed Liu CL, Chang YC, Cheng SP, Chern SR, Yang TL, Lee JJ, Guo IC, Chen CP: The roles of serum leptin concentration and polymorphism in leptin receptor gene at codon 109 in breast cancer. Oncology. 2007, 72: 75-81. 10.1159/000111097.CrossRefPubMed
29.
go back to reference Nava VE, Hobson JP, Murthy S, Milstien S, Spiegel S: Sphingosine kinase type 1 promotes estrogen-dependent tumorigenesis of breast cancer MCF-7 cells. Exp Cell Res. 2002, 281: 115-127. 10.1006/excr.2002.5658.CrossRefPubMed Nava VE, Hobson JP, Murthy S, Milstien S, Spiegel S: Sphingosine kinase type 1 promotes estrogen-dependent tumorigenesis of breast cancer MCF-7 cells. Exp Cell Res. 2002, 281: 115-127. 10.1006/excr.2002.5658.CrossRefPubMed
30.
go back to reference Zheng Q, Banaszak L, Fracci S, Basali D, Dunlap SM, Hursting SD, Rich JN, Hjlemeland AB, Vasanji A, Berger NA, Lathia JD, Reizes O: Leptin receptor maintains cancer stem-like properties in triple negative breast cancer cells. Endocr Relat Cancer. 2013, 20: 797-808. 10.1530/ERC-13-0329.CrossRefPubMedPubMedCentral Zheng Q, Banaszak L, Fracci S, Basali D, Dunlap SM, Hursting SD, Rich JN, Hjlemeland AB, Vasanji A, Berger NA, Lathia JD, Reizes O: Leptin receptor maintains cancer stem-like properties in triple negative breast cancer cells. Endocr Relat Cancer. 2013, 20: 797-808. 10.1530/ERC-13-0329.CrossRefPubMedPubMedCentral
31.
go back to reference Ray A, Nkhata KJ, Grande JP, Cleary MP: Diet-induced obesity and mammary tumor development in relation to estrogen receptor status. Cancer Lett. 2007, 253: 291-300. 10.1016/j.canlet.2007.02.005.CrossRefPubMed Ray A, Nkhata KJ, Grande JP, Cleary MP: Diet-induced obesity and mammary tumor development in relation to estrogen receptor status. Cancer Lett. 2007, 253: 291-300. 10.1016/j.canlet.2007.02.005.CrossRefPubMed
32.
go back to reference Sukocheva O, Wadham C, Holmes A, Albanese N, Verrier E, Feng F, Bernal A, Derian CK, Ullrich A, Vadas MA, Xia P: Estrogen transactivates EGFR via the sphingosine 1-phosphate receptor Edg-3: the role of sphingosine kinase-1. J Cell Biol. 2006, 173: 301-310. 10.1083/jcb.200506033.CrossRefPubMedPubMedCentral Sukocheva O, Wadham C, Holmes A, Albanese N, Verrier E, Feng F, Bernal A, Derian CK, Ullrich A, Vadas MA, Xia P: Estrogen transactivates EGFR via the sphingosine 1-phosphate receptor Edg-3: the role of sphingosine kinase-1. J Cell Biol. 2006, 173: 301-310. 10.1083/jcb.200506033.CrossRefPubMedPubMedCentral
33.
go back to reference Mukhopadhyay D, Tsiokas L, Zhou XM, Foster D, Brugge JS, Sukhatme VP: Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature. 1995, 375: 577-581. 10.1038/375577a0.CrossRefPubMed Mukhopadhyay D, Tsiokas L, Zhou XM, Foster D, Brugge JS, Sukhatme VP: Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature. 1995, 375: 577-581. 10.1038/375577a0.CrossRefPubMed
34.
go back to reference Sobue S, Murakami M, Banno Y, Ito H, Kimura A, Gao S, Furuhata A, Takagi A, Kojima T, Suzuki M, Nozawa Y, Murate T: v-Src oncogene product increases sphingosine kinase 1 expression through mRNA stabilization: alteration of AU-rich element-binding proteins. Oncogene. 2008, 27: 6023-6033. 10.1038/onc.2008.198.CrossRefPubMed Sobue S, Murakami M, Banno Y, Ito H, Kimura A, Gao S, Furuhata A, Takagi A, Kojima T, Suzuki M, Nozawa Y, Murate T: v-Src oncogene product increases sphingosine kinase 1 expression through mRNA stabilization: alteration of AU-rich element-binding proteins. Oncogene. 2008, 27: 6023-6033. 10.1038/onc.2008.198.CrossRefPubMed
35.
go back to reference Ohotski J, Edwards J, Elsberger B, Watson C, Orange C, Mallon E, Pyne S, Pyne NJ: Identification of novel functional and spatial associations between sphingosine kinase 1, sphingosine 1-phosphate receptors and other signaling proteins that affect prognostic outcome in estrogen receptor-positive breast cancer. Int J Cancer. 2013, 132: 605-616. 10.1002/ijc.27692.CrossRefPubMed Ohotski J, Edwards J, Elsberger B, Watson C, Orange C, Mallon E, Pyne S, Pyne NJ: Identification of novel functional and spatial associations between sphingosine kinase 1, sphingosine 1-phosphate receptors and other signaling proteins that affect prognostic outcome in estrogen receptor-positive breast cancer. Int J Cancer. 2013, 132: 605-616. 10.1002/ijc.27692.CrossRefPubMed
36.
go back to reference Gonzalez-Perez RR, Xu Y, Guo S, Watters A, Zhou W, Leibovich SJ: Leptin upregulates VEGF in breast cancer via canonic and non-canonical signalling pathways and NFkappaB/HIF-1alpha activation. Cell Signal. 2010, 22: 1350-1362. 10.1016/j.cellsig.2010.05.003.CrossRefPubMedPubMedCentral Gonzalez-Perez RR, Xu Y, Guo S, Watters A, Zhou W, Leibovich SJ: Leptin upregulates VEGF in breast cancer via canonic and non-canonical signalling pathways and NFkappaB/HIF-1alpha activation. Cell Signal. 2010, 22: 1350-1362. 10.1016/j.cellsig.2010.05.003.CrossRefPubMedPubMedCentral
37.
go back to reference Nakade Y, Banno Y, T-Koizumi K, Hagiwara K, Sobue S, Koda M, Suzuki M, Kojima T, Takagi A, Asano H, Nozawa Y, Murate T: Regulation of sphingosine kinase 1 gene expression by protein kinase C in a human leukemia cell line, MEG-O1. Biochim Biophys Acta. 2003, 1635: 104-116. 10.1016/j.bbalip.2003.11.001.CrossRefPubMed Nakade Y, Banno Y, T-Koizumi K, Hagiwara K, Sobue S, Koda M, Suzuki M, Kojima T, Takagi A, Asano H, Nozawa Y, Murate T: Regulation of sphingosine kinase 1 gene expression by protein kinase C in a human leukemia cell line, MEG-O1. Biochim Biophys Acta. 2003, 1635: 104-116. 10.1016/j.bbalip.2003.11.001.CrossRefPubMed
38.
go back to reference Kang ES, Oh MA, Lee SA, Kim TY, Kim SH, Gotoh N, Kim YN, Lee JW: EGFR phosphorylation-dependent formation of cell-cell contacts by Ras/Erks cascade inhibition. Biochim Biophys Acta. 2007, 6: 833-843. 10.1016/j.bbamcr.2007.02.003.CrossRef Kang ES, Oh MA, Lee SA, Kim TY, Kim SH, Gotoh N, Kim YN, Lee JW: EGFR phosphorylation-dependent formation of cell-cell contacts by Ras/Erks cascade inhibition. Biochim Biophys Acta. 2007, 6: 833-843. 10.1016/j.bbamcr.2007.02.003.CrossRef
39.
go back to reference Miao J, Xiao Z, Kanamaluru D, Min G, Yau PM, Veenstra TD, Ellis E, Strom S, Suino-Powell K, Xu HE, Kemper JK: Bile acid signaling pathways increase stability of Small Heterodimer Partner (SHP) by inhibiting ubiquitin-proteasomal degradation. Genes Dev. 2009, 23: 986-996. 10.1101/gad.1773909.CrossRefPubMedPubMedCentral Miao J, Xiao Z, Kanamaluru D, Min G, Yau PM, Veenstra TD, Ellis E, Strom S, Suino-Powell K, Xu HE, Kemper JK: Bile acid signaling pathways increase stability of Small Heterodimer Partner (SHP) by inhibiting ubiquitin-proteasomal degradation. Genes Dev. 2009, 23: 986-996. 10.1101/gad.1773909.CrossRefPubMedPubMedCentral
40.
go back to reference Hakak Y, Martin GS: Ubiquitin-dependent degradation of active Src. Curr Biol. 1999, 9: 1039-1042. 10.1016/S0960-9822(99)80453-9.CrossRefPubMed Hakak Y, Martin GS: Ubiquitin-dependent degradation of active Src. Curr Biol. 1999, 9: 1039-1042. 10.1016/S0960-9822(99)80453-9.CrossRefPubMed
41.
go back to reference Lu Z, Hunter T: Degradation of activated protein kinases by ubiquitination. Annu Rev Biochem. 2009, 78: 435-475. 10.1146/annurev.biochem.013008.092711.CrossRefPubMedPubMedCentral Lu Z, Hunter T: Degradation of activated protein kinases by ubiquitination. Annu Rev Biochem. 2009, 78: 435-475. 10.1146/annurev.biochem.013008.092711.CrossRefPubMedPubMedCentral
42.
go back to reference Bjorbaek C, Buchholz RM, Davis SM, Bates SH, Pierroz DD, Gu H, Neel BG, Myers MG, Flier JS: Divergent roles of SHP-2 in ERK activation by leptin receptors. J Biol Chem. 2001, 276: 4747-4755. 10.1074/jbc.M007439200.CrossRefPubMed Bjorbaek C, Buchholz RM, Davis SM, Bates SH, Pierroz DD, Gu H, Neel BG, Myers MG, Flier JS: Divergent roles of SHP-2 in ERK activation by leptin receptors. J Biol Chem. 2001, 276: 4747-4755. 10.1074/jbc.M007439200.CrossRefPubMed
43.
go back to reference Sengupta TK, Talbot ES, Scherle PA, Ivashkiv LB: Rapid inhibition of interleukin-6 signaling and Stat3 activation mediated by mitogen-activated protein kinases. Proc Natl Acad Sci U S A. 1998, 95: 11107-11112. 10.1073/pnas.95.19.11107.CrossRefPubMedPubMedCentral Sengupta TK, Talbot ES, Scherle PA, Ivashkiv LB: Rapid inhibition of interleukin-6 signaling and Stat3 activation mediated by mitogen-activated protein kinases. Proc Natl Acad Sci U S A. 1998, 95: 11107-11112. 10.1073/pnas.95.19.11107.CrossRefPubMedPubMedCentral
44.
go back to reference Aceto N, Sausgruber N, Brinkhaus H, Gaidatzis D, Martiny-Baron G, Mazzarol G, Confalonieri S, Quarto M, Hu G, Balwierz PJ, Pachkov M, Elledge SJ, van Nimwegen E, Stadler MB, Bentires-Alj M: Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop. Nat Med. 2012, 18: 529-537. 10.1038/nm.2645.CrossRefPubMed Aceto N, Sausgruber N, Brinkhaus H, Gaidatzis D, Martiny-Baron G, Mazzarol G, Confalonieri S, Quarto M, Hu G, Balwierz PJ, Pachkov M, Elledge SJ, van Nimwegen E, Stadler MB, Bentires-Alj M: Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop. Nat Med. 2012, 18: 529-537. 10.1038/nm.2645.CrossRefPubMed
45.
go back to reference Zhang SQ, Yang W, Kontaridis MI, Bivona TG, Wen G, Araki T, Luo J, Thompson JA, Schraven BL, Philips MR, Neel BG: Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. Mol Cell. 2004, 13: 341-355. 10.1016/S1097-2765(04)00050-4.CrossRefPubMed Zhang SQ, Yang W, Kontaridis MI, Bivona TG, Wen G, Araki T, Luo J, Thompson JA, Schraven BL, Philips MR, Neel BG: Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. Mol Cell. 2004, 13: 341-355. 10.1016/S1097-2765(04)00050-4.CrossRefPubMed
46.
go back to reference Long JS, Edwards J, Watson C, Tovey S, Mair KM, Schiff R, Natarajan V, Pyne NJ, Pyne S: Sphingosine kinase 1 induces tolerance to human epidermal growth factor receptor 2 and prevents formation of a migratory phenotype in response to sphingosine 1-phosphate in estrogen receptor-positive breast cancer cells. Mol Cell Biol. 2010, 30: 3827-3841. 10.1128/MCB.01133-09.CrossRefPubMedPubMedCentral Long JS, Edwards J, Watson C, Tovey S, Mair KM, Schiff R, Natarajan V, Pyne NJ, Pyne S: Sphingosine kinase 1 induces tolerance to human epidermal growth factor receptor 2 and prevents formation of a migratory phenotype in response to sphingosine 1-phosphate in estrogen receptor-positive breast cancer cells. Mol Cell Biol. 2010, 30: 3827-3841. 10.1128/MCB.01133-09.CrossRefPubMedPubMedCentral
47.
go back to reference Ohotski J, Long JS, Orange C, Elsberger B, Mallon E, Doughty J, Pyne S, Pyne NJ, Edwards J: Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associated with outcome in oestrogen receptor-negative breast cancer. Br J Cancer. 2012, 106: 1453-1459. 10.1038/bjc.2012.98.CrossRefPubMedPubMedCentral Ohotski J, Long JS, Orange C, Elsberger B, Mallon E, Doughty J, Pyne S, Pyne NJ, Edwards J: Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associated with outcome in oestrogen receptor-negative breast cancer. Br J Cancer. 2012, 106: 1453-1459. 10.1038/bjc.2012.98.CrossRefPubMedPubMedCentral
48.
go back to reference Pyne NJ, Tonelli F, Lim KG, Long J, Edwards J, Pyne S: Targeting sphingosine kinase 1 in cancer. Adv Biol Regul. 2012, 52: 31-38. 10.1016/j.advenzreg.2011.07.001.CrossRefPubMed Pyne NJ, Tonelli F, Lim KG, Long J, Edwards J, Pyne S: Targeting sphingosine kinase 1 in cancer. Adv Biol Regul. 2012, 52: 31-38. 10.1016/j.advenzreg.2011.07.001.CrossRefPubMed
49.
go back to reference Pchejetski D, Bohler T, Brizuela L, Sauer L, Doumerc N, Golzio M, Salunkhe V, Teissie J, Malavaud B, Waxman J, Cuvillier O: FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1. Cancer Res. 2010, 70: 8651-8661. 10.1158/0008-5472.CAN-10-1388.CrossRefPubMed Pchejetski D, Bohler T, Brizuela L, Sauer L, Doumerc N, Golzio M, Salunkhe V, Teissie J, Malavaud B, Waxman J, Cuvillier O: FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1. Cancer Res. 2010, 70: 8651-8661. 10.1158/0008-5472.CAN-10-1388.CrossRefPubMed
50.
go back to reference Pchejetski D, Doumerc N, Golzio M, Naymark M, Teissie J, Kohama T, Waxman J, Malavaud B, Cuvillier O: Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models. Mol Cancer Ther. 2008, 7: 1836-1845. 10.1158/1535-7163.MCT-07-2322.CrossRefPubMed Pchejetski D, Doumerc N, Golzio M, Naymark M, Teissie J, Kohama T, Waxman J, Malavaud B, Cuvillier O: Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models. Mol Cancer Ther. 2008, 7: 1836-1845. 10.1158/1535-7163.MCT-07-2322.CrossRefPubMed
51.
go back to reference Pchejetski D, Golzio M, Bonhoure E, Calvet C, Doumerc N, Garcia V, Mazerolles C, Rischmann P, Teissie J, Malavaud B, Cuvillier O: Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. Cancer Res. 2005, 65: 11667-11675. 10.1158/0008-5472.CAN-05-2702.CrossRefPubMed Pchejetski D, Golzio M, Bonhoure E, Calvet C, Doumerc N, Garcia V, Mazerolles C, Rischmann P, Teissie J, Malavaud B, Cuvillier O: Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. Cancer Res. 2005, 65: 11667-11675. 10.1158/0008-5472.CAN-05-2702.CrossRefPubMed
52.
go back to reference Antoon JW, White MD, Driver JL, Burow ME, Beckman BS: Sphingosine kinase isoforms as a therapeutic target in endocrine therapy resistant luminal and basal-A breast cancer. Exp Biol Med. 2012, 237: 832-844. 10.1258/ebm.2012.012028.CrossRef Antoon JW, White MD, Driver JL, Burow ME, Beckman BS: Sphingosine kinase isoforms as a therapeutic target in endocrine therapy resistant luminal and basal-A breast cancer. Exp Biol Med. 2012, 237: 832-844. 10.1258/ebm.2012.012028.CrossRef
53.
go back to reference Turkoz FP, Solak M, Petekkaya I, Keskin O, Kertmen N, Sarici F, Arik Z, Babacan T, Ozisik Y, Altundag K: The prognostic impact of obesity on molecular subtypes of breast cancer in premenopausal women. J BUON. 2013, 18: 335-341.PubMed Turkoz FP, Solak M, Petekkaya I, Keskin O, Kertmen N, Sarici F, Arik Z, Babacan T, Ozisik Y, Altundag K: The prognostic impact of obesity on molecular subtypes of breast cancer in premenopausal women. J BUON. 2013, 18: 335-341.PubMed
54.
go back to reference Chlebowski RT, Blackburn GL, Thomson CA, Nixon DW, Shapiro A, Hoy MK, Goodman MT, Giuliano AE, Karanja N, McAndrew P, Hudis C, Butler J, Merkel D, Kristal A, Caan B, Michaelson R, Vinciguerra V, Del Prete S, Winkler M, Hall R, Simon M, Winters BL, Elashoff RM: Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women’s Intervention Nutrition Study. J Natl Cancer Inst. 2006, 98: 1767-1776. 10.1093/jnci/djj494.CrossRefPubMed Chlebowski RT, Blackburn GL, Thomson CA, Nixon DW, Shapiro A, Hoy MK, Goodman MT, Giuliano AE, Karanja N, McAndrew P, Hudis C, Butler J, Merkel D, Kristal A, Caan B, Michaelson R, Vinciguerra V, Del Prete S, Winkler M, Hall R, Simon M, Winters BL, Elashoff RM: Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women’s Intervention Nutrition Study. J Natl Cancer Inst. 2006, 98: 1767-1776. 10.1093/jnci/djj494.CrossRefPubMed
Metadata
Title
Leptin induces upregulation of sphingosine kinase 1 in oestrogen receptor-negative breast cancer via Src family kinase-mediated, janus kinase 2-independent pathway
Authors
Heba Alshaker
Jonathan Krell
Adam E Frampton
Jonathan Waxman
Oleg Blyuss
Alexey Zaikin
Mathias Winkler
Justin Stebbing
Ernesto Yagüe
Dmitri Pchejetski
Publication date
01-10-2014
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 5/2014
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-014-0426-6

Other articles of this Issue 5/2014

Breast Cancer Research 5/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine